Bluejay Diagnostics
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
360 Massachusetts Ave Ste 203, Acton, Ma...Phone Number
(844) 327-7078Website
www.bluejaydx.comRevenue
<$5 MillionStock Symbol
BJDXIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Bluejay Diagnostics
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers Symphony platform, a technology platform comprising Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. It also provides ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, the company develops Symphony IL-6 test for the monitoring of disease progression in critical care settings. Further, it develops cardiac biomarkers, such as hsTNT and NT pro-BNP, as well as other tests using the Symphony platform. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.Explore more
Bluejay Diagnostics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Bluejay Diagnostics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Bluejay Diagnostics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Bluejay Diagnostics
Earning: See what the market has to say on Bluejay Diagnostics recently announced quarterly report
Funding: Get notified immidiatlly once Bluejay Diagnostics has new funding data
Bluejay Diagnostics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Bluejay Diagnostics launches new products
Click to see if Bluejay Diagnostics had a recent Job posting/layoffs
Check out if Bluejay Diagnostics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Bluejay Diagnostics as Masked Content
Find more new buyers
Compare Similar Companies to Bluejay Diagnostics
Compare insights from companies similar to Bluejay Diagnostics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Bluejay Diagnostics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Bluejay Diagnostics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Bluejay Diagnostics.
Bluejay Diagnostics Tech Stack
A closer look at the technologies used by Bluejay Diagnostics
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Earnings
Earnings, Finance
Earnings
Earnings, Finance
Person-Based
Operations
Person-Based
Product Development, Clinical Operations
Bluejay Diagnostics News & Media
Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization
ACTON, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on improving patient outcomes in critical care settings, today reported financial results for the quarter ended June 30, 2026 and provided an update on the Company’s clinical, regulatory and manufacturing progress.Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study
750 Patients Enrolled Ahead of Plan in Pivotal Study Evaluating Symphony™ IL-6 for Early Assessment of 28-Day Sepsis Mortality Risk 750 Patients Enrolled Ahead of Plan in Pivotal Study Evaluating Symphony™ IL-6 for Early Assessment of 28-Day Sepsis Mortality RiskBluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
$8.5 million upfront with up to approximately $15.2 million of potential additional gross proceeds upon the exercise in full of warrantsNorthstrive Fund II and Braeden Lichti exit Bluejay Diagnostics (BJDX) stake - Stock Titan
Amendment No. 1 to Schedule 13G shows Northstrive Fund II and Braeden Lichti now hold 0 shares, or 0.00%, of Bluejay Diagnostics common stock as of June 2, 2026.
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Bluejay Diagnostics
Sign Up For FreeTo access detailed company insights
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers Symphony platform, a technology platform comprising Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.... Read More
